These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28760963)

  • 21. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.
    Puhaindran ME; Farooki A; Steensma MR; Hameed M; Healey JH; Boland PJ
    J Bone Joint Surg Am; 2011 Jul; 93(13):1235-42. PubMed ID: 21776577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.
    Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC
    J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing?
    Ha KY; Park KS; Kim SI; Kim YH
    Osteoporos Int; 2016 Feb; 27(2):483-8. PubMed ID: 26202489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
    Soen S
    Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical femoral fractures related to bisphosphonate use: A comprehensive review of 19 patients.
    Şahin K; Ergin ON; Bayram S; Akgül T
    Ulus Travma Acil Cerrahi Derg; 2019 Nov; 25(6):603-610. PubMed ID: 31701502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How do bisphosphonates affect fracture healing?
    Kates SL; Ackert-Bicknell CL
    Injury; 2016 Jan; 47 Suppl 1(0 1):S65-8. PubMed ID: 26768295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonate-associated atypical subtrochanteric femur fracture.
    Wolin EA; Banks KP; Vroman PJ
    J Nucl Med Technol; 2015 Mar; 43(1):72-3. PubMed ID: 25125450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
    Miyakoshi N; Aizawa T; Sasaki S; Ando S; Maekawa S; Aonuma H; Tsuchie H; Sasaki H; Kasukawa Y; Shimada Y
    J Bone Miner Metab; 2015 Sep; 33(5):553-9. PubMed ID: 25227287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment.
    Yeh WL; Su CY; Chang CW; Chen CH; Fu TS; Chen LH; Lin TY
    BMC Musculoskelet Disord; 2017 Dec; 18(1):527. PubMed ID: 29237448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonates and atypical femoral fractures: Is the location of the fracture associated with the time of consolidation?
    Llano L; Barla J; Taype D; Garcia Barreiro G; Sancineto C; Carabelli G
    Injury; 2023 Nov; 54 Suppl 6():110730. PubMed ID: 38143116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
    Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
    JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
    Clout A; Narayanasamy N; Harris I
    J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis.
    Morales-Santana S; Díez-Pérez A; Olmos JM; Nogués X; Sosa M; Díaz-Curiel M; Pérez-Castrillón JL; Pérez-Cano R; Torrijos A; Jodar E; Rio LD; Caeiro-Rey JR; Reyes-García R; García-Fontana B; González-Macías J; Muñoz-Torres M
    Maturitas; 2015 Dec; 82(4):402-10. PubMed ID: 26358930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up.
    Png MA; Mohan PC; Koh JSB; Howe CY; Howe TS
    Osteoporos Int; 2019 Dec; 30(12):2417-2428. PubMed ID: 31435684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures.
    Ahn J; Kim CH; Kim JW
    Sci Rep; 2024 Aug; 14(1):19974. PubMed ID: 39198602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.
    Park-Wyllie LY; Mamdani MM; Juurlink DN; Hawker GA; Gunraj N; Austin PC; Whelan DB; Weiler PJ; Laupacis A
    JAMA; 2011 Feb; 305(8):783-9. PubMed ID: 21343577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonate use after clinical fracture and risk of new fracture.
    Bergman J; Nordström A; Nordström P
    Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.